Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

748.76 -2.01 (-0.27%)
Streaming Delayed Price Updated: 10:21 AM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
74 75 Next >
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
Via Investor's Business Daily
This Warren Buffett Stock Is On The Cusp Of Joining The $1 Trillion Club
Berkshire Hathaway is just below a $1 trillion market cap. 
Via Investor's Business Daily
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings. 
Via InvestorPlace
DexCom: A Winner In Diabetes Management
Diabetes management and glucose monitoring solutions provider DexCom, Inc. recently released its fourth-quarter results, reporting $1.0 billion in revenue, up 27% year-over-year compared to $820... 
Via Talk Markets
Is Eli Lilly Stock Going to $950? 1 Wall Street Analyst Thinks So.
The price tag may seem high already, but it might be just the start. 
Via The Motley Fool
Harvard Business Professor on Failing Well
Why would Eli Lilly put on a failure party? 
Via The Motley Fool
Assessing Eli Lilly and Co's Performance Against Competitors In Pharmaceuticals Industry
Via Benzinga
What the Options Market Tells Us About Eli Lilly and Co
Via Benzinga
3 Dividend Stocks That Are No-Brainer Buys Right Now
These stocks check off multiple boxes for investors. 
Via The Motley Fool
Obesity Solutions Like Weight Loss Drugs To Act As Catalyst For Economic Surge, Goldman Sachs Forecasts
Goldman Sachs predicts a potential 1% GDP boost from GLP-1 agonists market. Novo Nordisk and Eli Lilly lead, with analysts foreseeing 10-70 million users by 2028. AI-powered drug discovery and... 
Via Benzinga
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy. 
Via Investor's Business Daily
Could Eli Lilly Stock Help You Become a Millionaire?
Shares of Eli Lilly have risen by roughly 1,190% over the past 10 years. 
Via The Motley Fool
Here's 1 Pharmaceutical Stock That Looks Unstoppable. Hint: It's Not Novo Nordisk.
Eli Lilly is home to many blockbuster drugs including Mounjaro, Jardiance, Zepbound, and more. 
Via The Motley Fool
Eli Lilly Unusual Options Activity
Via Benzinga
Where Will Eli Lilly Be in 5 Years?
The stock will still be crushing the market in all likelihood. 
Via The Motley Fool
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
Why Eli Lilly Stock Was Feeling Sickly on Wednesday
The company's surging popularity has made it expensive in terms of valuation. 
Via The Motley Fool
Wall Street Favorites: 7 Growth Stocks With Strong Buy Ratings for February 2024
Here are just a few of the top growth stocks investors may want to seriously consider as we get deeper into the new year. 
Via InvestorPlace
3 Stocks With the Potential to Knock Tesla Out of the Magnificent 7
These stocks are best positioned to usurp Tesla's position within Magnificent 7 stocks as it slumps further in February. 
Via InvestorPlace
Health Care Becomes Most Overweighted Sector As Hedge Funds Crowd Into Magnificent 7
Goldman Sachs' Hedge Fund Trend Monitor highlights concentration in mega-caps, with optimism in AI and health care. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Eli Lilly Has More Than an Ozempic Competitor -- Much More
Eli Lilly's hottest treatment might be Mounjaro, but the company has a lot more at its disposal. 
Via The Motley Fool
Abbott Laboratories Stock Gets A Healthy Technical Rating Upgrade
In a welcome move, Abbott Laboratories stock saw its Relative Strength Rating improve from 67 to 73 on Wednesday. 
Via Investor's Business Daily
3 Top Sectors Investment Dollars Are Pouring Into Now: February 2024
Predicting top sectors isn't easy; we usually identify them only in hindsight, but these three stock market segments are rapidly rising. 
Via InvestorPlace
3 Cheap Dividend Stocks to Snatch Up Now
Cheap dividend stocks offer rebound upside paired with an income source that is difficult to beat for most investors. 
Via InvestorPlace
Top 7 Contenders to Join the Trillion-Dollar Club
Microsoft's ascent to the $3 trillion mark highlights the growing influence of trillion-dollar companies in the stock market. 
Via InvestorPlace
Eli Lilly & Company Should Continue Bullish Rally
Eli Lilly & Company discovers, develops & markets human pharmaceuticals worldwide. It is having around 742 B$ market cap as of 16 February 2024. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Magnificent Growth Stocks to Buy Right Now
These stocks share at least two common denominators: a biopharmaceutical focus and great long-term prospects. 
Via The Motley Fool
3 Stocks Primed to Reach Trillion-Dollar Valuation
Explore the elite world of trillion-dollar stocks and uncover insights on the companies dominating the market with unparalleled valuations. 
Via InvestorPlace
Warren Buffett's Empire Nears Trillion-dollar Club As Class A Shares Hit Above $600,000
This week, Berkshire Hathaway (NYSE: BRK-A) achieved a historic milestone as its Class A shares closed above $600,000 for the first time. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
74 75 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.